Sept. 9 Clinical Quick Takes: Translate to discontinue enzyme deficiency candidate; plus Janssen, Neurotrope, AMT and Cassava

Translate dropping enzyme deficiency program
Translate Bio Inc. (NASDAQ:TBIO) fell $0.73 to $9.25 in after-hours trade Monday after the company said that it is discontinuing development of MRT5201 for ornithine transcarbamylase deficiency based on preclinical safety and PK profiles for the lipid nanoparticle-encapsulated

Read the full 420 word article

User Sign In